The Biomarkers & Advanced Technologies Market in 2026

The US biomarkers advanced technologies market was valued at $235.94 billion in 2024 and is projected to reach $541.32 billion by 2035, a 7.84% compound annual growth rate, according to Market Research Future. That figure spans everything from molecular diagnostics reagents to biomarker discovery software, which is exactly why a generic "healthcare" business plan template doesn't hold up here — a liquid-biopsy assay developer, a companion-diagnostic co-development partner, and a wearable-sensor digital-biomarker platform are three fundamentally different businesses with different cost structures, different regulators, and different buyers, even though all three sit inside the same headline market number.

Zoom out to the broader biomarkers category — including research-use-only reagents and clinical assays across all indications — and Fortune Business Insights puts the global market at $86.95 billion in 2025, growing to $217.58 billion by 2034 at a 12.20% CAGR. Two sub-segments are growing faster than the category average: digital biomarkers (wearable- and sensor-derived measures) are forecast to expand from $4.8 billion in 2025 to $60.6 billion by 2035, per Global Market Insights, and AI-assisted biomarker discovery is expected to grow from $3.8 billion in 2025 to $11.2 billion by 2034, according to Market Intelo.

The UK's closest verified proxy is the in-vitro-diagnostics market, worth $4.58 billion in 2026 and forecast to reach $6.57 billion by 2031 (7.48% CAGR), per Mordor Intelligence. Thermo Fisher Scientific, Siemens Healthineers, Abbott Laboratories, QIAGEN and Roche are named as the dominant suppliers in that market — useful context if you're pricing against incumbents rather than competing with them directly, which is the more realistic starting position for most new entrants.

What's actually driving demand isn't abstract "digital health growth" — it's regulatory pull. Eighteen oncology drugs now carry a mandatory biomarker prerequisite before a clinician can prescribe them, which creates captive, recurring demand for the assays that determine eligibility (Roche's Ventana platform, Thermo Fisher's Oncomine panels and Illumina's TruSight assays are the incumbent examples). A new entrant doesn't need to out-market Roche; it needs to find the biomarker, indication, or data modality the big platforms haven't covered yet, and build a plan a lender or grant panel can actually underwrite.

The market breaks into three segments with genuinely different economics, and a plan that treats them as one thing tends to confuse the reader in the first two pages:

• Protein and molecular biomarkers — ELISA and mass-spec-based assays, the largest and most mature segment, dominated by Abbott, QIAGEN, Hoffmann-La Roche, Thermo Fisher and Siemens Healthcare, per Market Research Future's list of major US players
• Genomic and genetic biomarkers — sequencing-based panels (NGS, liquid biopsy) where growth is fastest inside oncology companion diagnostics, and where Illumina and newer entrants like AccuraGen compete on turnaround time and detection sensitivity
• Digital biomarkers — wearable- and sensor-derived measures, the smallest segment today but the fastest-growing of the three, where the buyer is more often a pharma sponsor or health system than an individual patient

Buyer type follows the same split. Pharma R&D teams buy biomarker validation and companion-diagnostic partnerships; health systems and payers buy diagnostic testing capacity and, increasingly, digital monitoring subscriptions; direct-to-consumer wellness buyers exist but are a much smaller and lower-margin market than most first-time founders assume before they've priced CLIA compliance against a sub-$100 consumer price point.

Funding Routes: SBIR, SBA and Grant Options

Biomarker and diagnostics ventures rarely fund themselves the way a retail or hospitality business does. The R&D-heavy, multi-year validation timeline means non-dilutive government funding, equipment-secured loans, and specialist life-science investors carry more weight in the capital stack than a standard bank overdraft or a generic small-business loan.

United States

NIH SBIR/STTR grants are the default first stop. Phase I awards provide up to roughly $275,000 in non-dilutive funding for early-stage diagnostics, device and biomarker discovery work, and NIH distributes more SBIR/STTR funding than any other civilian agency — over $1.2 billion a year across 24 institutes and centers, per NIH's Seed Fund programme. Standard application deadlines fall on September 5, January 5 and April 5 each year, so a business plan built around a Q3 or Q1 SBIR submission needs its budget narrative finished well ahead of those dates, not the week before.

Once past the grant-funded discovery stage, an SBA 7(a) loan becomes viable for the equipment and lab facility side of the business — buying a qPCR system or fitting out a leased BSL-2 space is a bankable, asset-backed use of funds that a lender can underwrite, even if the underlying science is still pre-revenue. That's a different funding lever from equity: a founder who has already banked SBIR funding, has signed letters of intent from a pharma partner, or has a CLIA lab lease in hand has a materially stronger 7(a) application than one pitching the science alone. Series-stage examples show the ceiling on private capital in this space — liquid-biopsy startup AccuraGen raised a $40 million Series B round to commercialise its Firefly liquid-biopsy platform, per BioSpace, which is the scale of raise a fully validated, revenue-generating diagnostics platform can command.

United Kingdom and beyond

UK founders typically combine an Innovate UK Smart Grant (non-dilutive, competitive, awarded on technical and commercial merit) with SEIS or EIS-eligible angel investment once the company has formal share capital in place. A university spin-out with existing IP is in the strongest position here, since the grant panel is assessing both the science and the team's ability to execute a regulatory pathway — exactly the section a generic business plan template skips and a bespoke one has to get right. Smart Grants typically part-fund a majority share of eligible project costs for small businesses rather than covering the whole budget, so the plan still needs to show where the remaining cash comes from — usually a blend of founder capital, an SEIS-eligible angel round, and the value of any university-licensed lab space or equipment access contributed in kind. Canada's IRAP programme and Australia's R&D Tax Incentive serve a similar non-dilutive role in those markets for biomarker and diagnostics R&D spend.

Whichever jurisdiction you're funding from, grant and lender reviewers are reading your plan for the same signal: does the founder understand that a positive lab result is not the same thing as a fundable business? A plan that spends three pages on the science and one paragraph on CLIA timeline, reimbursement strategy and go-to-market rarely survives diligence, however strong the underlying data is.

What It Actually Costs to Launch

Launching a biomarker or diagnostics venture typically requires $180,000 to $1.4 million (£142,000 to £1.1 million) in initial capital. The single biggest swing factor is whether you own core lab equipment outright or outsource sequencing and mass spectrometry to a contract research organisation during your validation phase — that decision alone can move total startup capital by half a million dollars.

A sixth line item founders regularly underweight: IP filing. Budget $15,000 to $60,000 for a US provisional plus a UK or PCT patent application on the underlying biomarker, algorithm or assay design — filed before, not after, you start showing the assay to potential pharma partners or investors. A biomarker with no filed IP is much harder to license later, and pharma due-diligence teams check filing dates as a matter of routine.

The lean-versus-full-build decision isn't just about cash — it's about what a funder wants to see. A grant panel evaluating a Phase I SBIR application generally prefers the lean route: outsourcing sequencing or mass spectrometry to a CRO keeps burn low and proves the science before you've sunk capital into an instrument. A lender evaluating an SBA 7(a) application wants the opposite: owned equipment is collateral, which is precisely why founders who've already banked a grant and signed a pharma letter of intent are in a stronger position to finance the full build-out with debt rather than diluting further with equity. The two funding routes reward two different capital strategies, and the plan should be explicit about which one it's pursuing at each stage rather than blending both into one vague "we'll figure it out" budget line.

Lab Equipment and Platform Costs, Itemised

Equipment is where a biomarker business plan lives or dies with a lender or grant panel — vague line items like "lab equipment: $200,000" read as a founder who hasn't actually priced the build-out. Named systems and realistic ranges:

• MALDI-TOF mass spectrometer (protein/peptide biomarker ID): $100,000–$250,000, per Excedr's pricing guide, plus consumables, software and a service contract on top of the purchase price
• qPCR system (nucleic-acid biomarker quantification, e.g. Bio-Rad CFX or Thermo Fisher QuantStudio): $25,000–$70,000
• Next-generation sequencing platform (Illumina NextSeq or MiSeq class): $125,000–$300,000, or pay per-run through a sequencing core/CRO at $500–$2,000 per sample if you're not ready to own the instrument
• ELISA plate reader and automated washer (protein biomarker immunoassays): $15,000–$45,000
• -80°C ultra-low freezers and biobanking storage: $8,000–$25,000 per unit, typically 2–4 units at launch
• Class II biosafety cabinet: $8,000–$20,000
• LIMS (Laboratory Information Management System) software for CLIA-compliant sample tracking: $500–$3,000/month, subscription-based (Benchling and LabWare are the two most commonly cited platforms in early-stage diagnostics labs)

Agilent Technologies and Bruker Corporation are the other two names that show up repeatedly on the supplier side of biomarker platform tenders, alongside Thermo Fisher, Illumina and Bio-Rad — worth requesting quotes from at least two of them before finalising a capital budget, since list price and actual negotiated price for a first-time lab buyer can differ by 15–20%.

Build-versus-outsource is the single decision that reshapes this entire list. Paying a sequencing core or contract research organisation $500–$2,000 per sample defers the $125,000–$450,000 platform purchase entirely, at the cost of a longer per-sample turnaround and less control over queue priority — usually the right trade for a pre-revenue company still proving analytical validity. Once monthly sample volume crosses roughly 150–200 tests, the per-sample CRO cost typically exceeds the amortised cost of owning the instrument outright, which is the point most business plans should model as the trigger for a Series A or second grant round earmarked specifically for equipment.

How Biomarker and Diagnostics Companies Make Money

There are three distinct revenue models in this space, and most successful business plans commit to one as the primary engine rather than trying to run all three at once from day one.

1. Fee-for-service diagnostic testing

You run the assay, bill per sample through CPT reimbursement codes, and collect from insurers or self-paying patients. Typical billing ranges from $150 to $1,200 per test depending on panel complexity. Worked example: a CLIA-certified lab running a 12-marker molecular panel at $420 per test, processing 400 samples a month at a 70% payer-collection rate, generates roughly $141,000 in monthly billings (400 × $420 × 0.70). After reagents and sequencing consumables (around 30% of revenue), lab staff and compliance overhead, that scale of operation typically nets a low-to-mid teens margin in year one, improving toward 20–28% once volume absorbs the fixed cost of the CLIA lab and quality system.

The 70% collection rate in that example is doing more work than it looks like. Payer mix — the split between commercial insurance, Medicare/Medicaid or NHS-equivalent public funding, and self-pay — drives both the average reimbursement per test and how long it takes to collect it. A lab weighted toward commercial payers typically collects faster and at a higher average rate than one weighted toward public programmes, but commercial payers also demand more prior-authorisation paperwork per test. A business plan that states an assumed payer mix explicitly, rather than quoting a single blended reimbursement figure, gives a lender or investor something they can actually stress-test against their own experience of the category.

2. Biomarker licensing and companion-diagnostic co-development

Instead of running tests yourself, you license the validated biomarker or assay to a pharmaceutical partner developing a targeted therapy. Deal structures typically combine an upfront fee of $250,000 to $2 million with milestone payments tied to regulatory approval and ongoing royalties on the companion diagnostic once commercialised. This is the highest-margin model in the category, but it depends on having defensible IP and clinical validation data strong enough to survive a pharma partner's due diligence — which is why the IP-filing timing point above matters so much.

3. Digital-biomarker platform subscription

If your product is software that derives a biomarker from wearable, sensor or app-based data (heart rate variability, gait, sleep architecture, speech patterns), revenue is typically SaaS-style: $500 to $5,000 a month per enterprise client, usually a pharma sponsor running a clinical trial, a health system, or a payer running a remote-monitoring programme. Empatica is the clearest example of a company that has commercialised this model — it holds six FDA-cleared digital biomarkers (pulse rate, respiratory rate, SpO2, skin temperature, electrodermal activity and sleep detection), per Empatica's own product documentation, which lets it sell validated measurement as a subscription rather than a one-off device. Biofourmis and Evidation Health run variants of the same model, layering AI-driven analytics on top of wearable data streams for pharma and payer clients.

Blending models as the business matures

Few biomarker ventures stay on a single revenue model for long. A realistic five-year plan usually shows fee-for-service testing carrying close to 100% of revenue in year one, since it's the fastest path to first billable dollars once CLIA/UKAS certification lands. By year three, a validated panel with two or three years of real-world outcome data is a credible licensing asset — plans that model 30–40% of year three revenue coming from a single companion-diagnostic or data-licensing deal, alongside continued per-sample billing, tend to read as more grounded to a lender or investor than plans that either ignore licensing upside entirely or lean on it as the sole growth driver from month one.

Licensing, Certification and Regulatory Approval

United States

• CLIA certification from CMS — required to run any clinical test on human specimens; $180 to $8,000+ annual fee depending on test complexity and volume, 2–4 months to obtain
• 510(k) premarket notification — for lower-risk biomarker assays and devices; roughly $24,000 standard FY2025 FDA user fee (small-business fee reductions available), 3–6 months review
• PMA (Premarket Approval) — required for most companion diagnostics; roughly $541,000 standard FY2025 FDA user fee plus $500,000–$2 million+ in clinical validation data generation, with a 180-day formal review target once accepted
• CAP accreditation (College of American Pathologists) — not legally mandatory alongside CLIA in every state, but frequently required by payers and pharma partners as a quality signal
• State-level clinical laboratory licensure — several states layer their own approval on top of CLIA before a lab can accept samples from their residents; New York's State Department of Health Clinical Laboratory Evaluation Program (CLEP) is the most commonly cited example and typically adds several months to a launch timeline if a lab wants to accept New York-origin samples from day one

For sponsors developing a drug and its companion diagnostic together, a realistic integrated programme runs four to six years from biomarker confirmation to regulatory approval of both products — a timeline that needs to be reflected honestly in your financial model, not compressed to make the numbers look better for a first pitch.

United Kingdom

• UKAS accreditation to ISO 15189 (medical laboratories) or ISO 17025 — £3,000–£15,000 in assessment fees plus ongoing surveillance visits, 6–12 months
• MHRA registration of your in-vitro diagnostic and any performance evaluation study, with the December 2025 MHRA roadmap requiring real-world safety data submission within 30 days of an adverse event and notified-body review for high-risk assays, per Lexology's summary of the MHRA IVD reform roadmap
• HTA licensing (Human Tissue Authority) if the venture stores or processes human tissue samples for biobanking

European Union and other jurisdictions

The EU's In Vitro Diagnostic Regulation (IVDR, 2017/746) classifies devices into Classes A through D by risk; most novel biomarker assays fall into Class C or D, which requires notified-body conformity assessment before a CE mark can be issued — a materially longer and more document-heavy process than the old IVD Directive it replaced. The UK's own post-Brexit IVD framework is now converging toward IVDR-equivalent requirements rather than diverging from them, so a business plan that assumes UK and EU pathways will stay meaningfully different is likely to be wrong within the plan's own five-year horizon.

Outside the US, UK and EU, the regulatory picture is patchy enough that a plan targeting a genuinely global rollout should treat each additional jurisdiction as its own line item rather than assuming one dossier transfers cleanly. Canada's Health Canada medical device licensing, Australia's TGA framework and Singapore's HSA process each have their own timelines and evidentiary requirements, and a founder who has only budgeted for FDA and MHRA will find the third market adds cost and delay that the financial model never accounted for. Most first-time biomarker plans are better served by naming one or two target markets explicitly and treating the rest as a stated future-expansion assumption, rather than pretending a US/UK launch plan is secretly a global one.

Five Mistakes That Sink First-Time Biomarker Ventures

We've reviewed enough biomarker and diagnostics plans at Avvale to notice the same five failure modes recurring, almost always because the founder is a strong scientist writing their first commercial document rather than a weak scientist with a bad idea. None of these are fatal if caught before the plan goes in front of a funder — all five are fatal if a reviewer catches them first.

• Treating validation like a software MVP. A biomarker assay can't be "shipped and iterated" the way an app can — analytical and clinical validation take months to years, and a financial model that assumes software-speed timelines runs out of cash before the science is provable.
• Filing IP after, not before, showing the assay around. Pharma and investor due diligence checks patent filing dates. A biomarker or algorithm disclosed at a conference or in a pitch deck before a provisional filing can lose novelty and, with it, licensing value.
• Ignoring reimbursement strategy until the test is already validated. CPT coding and payer coverage decisions can take longer than the assay validation itself. Plans that treat billing as an afterthought routinely discover, post-launch, that there's no clean reimbursement path for their specific panel.
• Underestimating CLIA/UKAS lead time in the cash-flow model. A 2–4 month CLIA timeline (or 6–12 month UKAS timeline) sitting between "lab is built" and "lab can bill a single test" is exactly the gap that causes an otherwise well-funded startup to run out of runway.
• Defaulting to PMA/Class III without checking cheaper pathways. Many assays can legally launch as a laboratory-developed test or via the 510(k)/Class II route at a fraction of the $500K–$2M+ PMA cost — but only if the regulatory strategy section of the plan actually interrogates which pathway fits, rather than assuming the most expensive one by default.

A sixth pattern worth naming separately because it's less about the science and more about the pitch: leading a business plan or investor deck with the biology rather than the buyer. A reviewer who has seen a hundred biomarker pitches has also seen a hundred slides explaining why a novel protein signature is scientifically elegant. What separates a fundable plan from an unfundable one is usually the next question — who pays for this test, how much, and how do you know that today, not eventually. Plans that open with the commercial answer and use the science to support it consistently outperform plans that do the reverse, even when the underlying assay is objectively stronger in the latter case.

Inside a Real Biomarker Business Plan

Here's an extract from a real biomarker/diagnostics business plan written by our team, so you can see exactly what the finished document looks like. Notice what's absent as much as what's present: no promise of a cure, no fabricated market-share number, and a breakeven month that reflects a real UKAS accreditation timeline rather than an optimistic guess.

What's in the Template

A biomarker or diagnostics business plan has to do double duty: it needs to satisfy a scientific reviewer who wants to see the validation logic hold up, and a financial reviewer who wants to see the regulatory timeline reflected honestly in the cash-flow model. Every Avvale business plan template includes these sections, pre-structured for your industry so both readers get what they need:

• Executive Summary — Your venture at a glance, written to hold a grant panel or investor's attention in 60 seconds
• Company Overview — Legal structure, IP position, founding team credentials and location
• Industry Analysis — Market size, growth trends, and the specific regulatory pathway your assay needs
• Customer/Partner Analysis — Whether you're selling to payers, pharma, health systems or patients directly, and what each buyer actually evaluates
• Competitor Analysis — Mapping incumbent platforms and where your assay, panel or data modality is genuinely differentiated
• Regulatory & Reimbursement Strategy — CLIA/UKAS pathway, FDA/MHRA classification decision, and CPT coding plan
• Operations Plan — Lab workflow, sample logistics, staffing structure and validation milestones
• Management Team — Founder scientific credentials, advisory board and key technical hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis and the startup-capital requirement structured for SBIR, SBA and Innovate UK submission formats. Working on an adjacent life-sciences venture? See our molecular diagnostics business plan template, the market research and content service, or speak with a consultant directly via our business plan writer page.

Frequently Asked Questions